SubHero Banner

Pemazyre (pemigatinib) – New orphan drug approval

April 17, 2020 - FDA announced the approval of Incyte’s Pemazyre (pemigatinib), for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Download PDF